Evolus, Inc.
No enriched coverage for $EOLS in the last 7 days.
Evolus (EOLS) reported Q2 2026 revenue of $84.1M, up 21% YoY, and positive Adjusted EBITDA of $4.7M. The company raised full-year revenue guidance to $330M-$337M and adjusted gross profit margin guidance to 67.0%-67.5%. Evolus expanded its customer base and loyalty program, while investing in new product launches and partnerships.
Pro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
MOATAZEDI DAVID (See Remarks) sold 105,108 shares of Evolus, Inc. (EOLS) at $9.04 ($0.95M total) on 2026-09-02.
Recent EOLS coverage spans earnings, financial news and corporate actions.
In the last 30 days, EOLS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($950K). The most active reporter was MOATAZEDI DAVID, See Remarks, with 1 filing.
Profitability milestone and higher guidance may boost investor sentiment.
Revenue growth and narrowing losses suggest improving fundamentals.
The insider sale may signal weak confidence, potentially pressuring the stock short-term.
Strong earnings outlook may sustain the price rally.
Guidance raise plus third consecutive quarter of positive adjusted EBITDA can re-rate near-term expectations and support momentum trades.
AlphAI scores every news story that mentions EOLS with an AI model for sentiment and relevance, and aggregates insider trades from Evolus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evolus (EOLS) reported Q2 2026 revenue of $84.1M, up 21% YoY, and positive Adjusted EBITDA of $4.7M. The company raised full-year revenue guidance to $330M-$337M and adjusted gross profit margin guidance to 67.0%-67.5%. Evolus expanded its customer base and loyalty program, while investing in new product launches and partnerships.
2 min readPro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
2 min readMOATAZEDI DAVID (See Remarks) sold 105,108 shares of Evolus, Inc. (EOLS) at $9.04 ($0.95M total) on 2026-09-02.
1 min readRenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
3 min readEvolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook • Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Re
4 min readEvolus said it expanded its partnership with Symatese to commercialize the Estyme injectable hyaluronic acid gel collection in Canada, Australia, and New Zealand. The deal, first announced in 2023, is expected to begin commercialization in 2028. Evolus also said it will hold exclusive rights in markets where it sells Jeuveau and Nuceiva. Shares were about $6.04.
2 min readEvolus, Inc. (EOLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme ® in Canada, Australia, and New Zealand Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau ® and Nuceiva ® across all Evolus commercial markets Further leverages Ev
4 min readEvolus Inc. said it signed an exclusive licensing and distribution deal with Swiss firm IBSA to develop and commercialize Profhilo in the U.S. Evolus will manage U.S. regulatory development and commercialization after approval. Profhilo is an injectable skin treatment launched in Europe in 2015 that stimulates collagen. Evolus shares were about $6.90.
2 min readEvolus (NASDAQ:EOLS) said it signed an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, an injectable skin-quality product, in the United States. Evolus will handle U.S. regulatory development and commercialization. The deal has no upfront payments and uses a transfer-price model, and Evolus said it will not affect its 2026 or 2028 outlook.
4 min readEvolus, Inc. (EOLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. eols-20260707 0001570562 false 0001570562 2026-07-07 2026-07-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min read
